Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Medication is not a quick fix for obesity, Dr. Samuel L. Wilcox said during a "Lunch & Learn" session at the Iola Public ...

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...